CL2014002861A1 - Metodo para tratar las dermatosis sensibles a los esteroides que comprende administrar n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida o n-{(1s)-2-amino-1-[(3,4-difluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-furanocarboxamida; y composicion que los comprende. - Google Patents

Metodo para tratar las dermatosis sensibles a los esteroides que comprende administrar n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida o n-{(1s)-2-amino-1-[(3,4-difluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-furanocarboxamida; y composicion que los comprende.

Info

Publication number
CL2014002861A1
CL2014002861A1 CL2014002861A CL2014002861A CL2014002861A1 CL 2014002861 A1 CL2014002861 A1 CL 2014002861A1 CL 2014002861 A CL2014002861 A CL 2014002861A CL 2014002861 A CL2014002861 A CL 2014002861A CL 2014002861 A1 CL2014002861 A1 CL 2014002861A1
Authority
CL
Chile
Prior art keywords
chloro
methyl
pyrazol
ethyl
amino
Prior art date
Application number
CL2014002861A
Other languages
English (en)
Spanish (es)
Inventor
Pankaj Agarwal
Vinod Kumar
Qing Xie
Original Assignee
Glaxosmithkline Intellectual Property N 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48143295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002861(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Intellectual Property N 2 Ltd filed Critical Glaxosmithkline Intellectual Property N 2 Ltd
Publication of CL2014002861A1 publication Critical patent/CL2014002861A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014002861A 2012-04-24 2014-10-23 Metodo para tratar las dermatosis sensibles a los esteroides que comprende administrar n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida o n-{(1s)-2-amino-1-[(3,4-difluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-furanocarboxamida; y composicion que los comprende. CL2014002861A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261637390P 2012-04-24 2012-04-24
US201361782565P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
CL2014002861A1 true CL2014002861A1 (es) 2015-01-16

Family

ID=48143295

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002861A CL2014002861A1 (es) 2012-04-24 2014-10-23 Metodo para tratar las dermatosis sensibles a los esteroides que comprende administrar n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida o n-{(1s)-2-amino-1-[(3,4-difluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-furanocarboxamida; y composicion que los comprende.

Country Status (26)

Country Link
US (2) US20150087683A1 (https=)
EP (1) EP2841053A1 (https=)
JP (1) JP2015514792A (https=)
KR (1) KR20150010943A (https=)
CN (1) CN104302275A (https=)
AR (1) AR090795A1 (https=)
AU (1) AU2013254849B2 (https=)
BR (1) BR112014026706A2 (https=)
CA (1) CA2873751A1 (https=)
CL (1) CL2014002861A1 (https=)
CO (1) CO7111283A2 (https=)
CR (1) CR20140491A (https=)
DO (1) DOP2014000238A (https=)
EA (1) EA201491914A1 (https=)
HK (1) HK1201726A1 (https=)
IL (1) IL235159A0 (https=)
MX (1) MX2014012904A (https=)
NZ (1) NZ628394A (https=)
PE (1) PE20142356A1 (https=)
PH (1) PH12014502400A1 (https=)
SG (1) SG11201406409VA (https=)
TW (1) TW201347758A (https=)
UA (1) UA113875C2 (https=)
UY (1) UY34762A (https=)
WO (1) WO2013160222A1 (https=)
ZA (1) ZA201407345B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821299A (zh) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 噻吩衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002734A1 (en) * 2004-07-01 2006-01-12 Unilever N.V. Moisture barrier
ES2368930T3 (es) * 2004-09-06 2011-11-23 Bayer Pharma Aktiengesellschaft Pirazolopirimidinas como inhibidores de proteína cinasa b (akt).
AU2006235314B2 (en) * 2005-04-12 2011-01-20 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN102405047B (zh) * 2009-01-30 2014-07-09 葛兰素史密斯克莱有限责任公司 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
JP2013507382A (ja) * 2009-10-08 2013-03-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
WO2011146710A1 (en) * 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination

Also Published As

Publication number Publication date
AR090795A1 (es) 2014-12-10
MX2014012904A (es) 2014-11-21
EA201491914A1 (ru) 2015-01-30
AU2013254849A1 (en) 2014-11-06
SG11201406409VA (en) 2014-11-27
US20160143885A1 (en) 2016-05-26
TW201347758A (zh) 2013-12-01
CN104302275A (zh) 2015-01-21
CR20140491A (es) 2014-12-22
ZA201407345B (en) 2015-11-25
UA113875C2 (uk) 2017-03-27
CO7111283A2 (es) 2014-11-10
AU2013254849B2 (en) 2016-05-26
US20150087683A1 (en) 2015-03-26
BR112014026706A2 (pt) 2017-06-27
HK1201726A1 (en) 2015-09-11
PH12014502400A1 (en) 2015-01-12
KR20150010943A (ko) 2015-01-29
CA2873751A1 (en) 2013-10-31
PE20142356A1 (es) 2015-01-30
EP2841053A1 (en) 2015-03-04
DOP2014000238A (es) 2014-12-15
IL235159A0 (en) 2014-12-31
WO2013160222A1 (en) 2013-10-31
UY34762A (es) 2013-11-29
JP2015514792A (ja) 2015-05-21
NZ628394A (en) 2016-02-26

Similar Documents

Publication Publication Date Title
BR112014028645A2 (pt) composições e métodos para modulação da expressão de apoa1 e abca1.
BR112014024182A2 (pt) compostos de poliorganossiloxano, processo para fabricação dos ditos compostos, composição e emulsão compreendendo os ditos compostos e método para tratamento de superfície compreendendo os ditos compostos
IL245062A0 (en) 1 -(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4h-pyrido[2, 3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as raf inhibitors for the treatment of cancer
DK3470063T3 (da) Farmaceutiske sammensætninger til behandling af cftr-medierede sygdomme
BR112015006996A2 (pt) método para reduzir a quantidade de enxofre em uma composição que compreende enxofre, e, composição.
BR112014030066A2 (pt) processo para a fabricação de uma composição de dialquil furan-2, 5-dicarboxilato (dafd), e, composição.
BR112015001577A2 (pt) agente de emulsificação, produto alimentício, método para a fabricação de um produto alimentício e agente de emulsificação e de estabilização.
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
BR112014007619A2 (pt) composição cosmética, e, método para melhorar pelo menos uma propriedade
BR112013014571A2 (pt) equipamento terapêutico, equipamento de radioterapia, produto de programa de computador e método para o controle de um equipamento terapêutico
CL2015001065A1 (es) Compuestos tolilo sustituidos; composición fungicida que los comprende; y método de control de enfermedades causadas por patógenos fúngicos en plantas.
BR112013024402A2 (pt) processo para produtos terapêuticos encapsulados e usos dos mesmos
ME03392B (me) Prolek derivati (e)-n-meтil-n-( (з-метi lbenzofuran-2-il)meтil)-3-(7 -okso-5 ,6, 7,8-тетrанidr0-1,8-nafтiridin-3-il)akrilamida
FR3006800B1 (fr) Procede d'approche d'une plateforme
FI20125631L (fi) Menetelmä ja järjestelmä pakkausmateriaalin valmistamiseksi sekä pakkausmateriaali ja pakkaus
CL2015000732A1 (es) Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.
BR112015007975A2 (pt) processo para preparar continuamente tetrapolímeros, e tetrapolímero
BR112015001569A2 (pt) processo de preparação de alcoxifenol, processo de preparação de alcoxihidroxibenzaldeído e processo de preparação de pelo menos um composto alcoxihidroxibenzaldeído.
EP2681198A4 (en) NEW LITTLE MOLECULES AS THERAPIES
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
BR112014020545A2 (pt) composição aquosa tópica estável, processo para o preparo da composição aquosa tópica estável e método para o tratamento de acne
BR112015027752A2 (pt) embalagem para conter pelo menos um artigo, matriz para formar uma embalagem para conter pelo menos um artigo, e método para formar uma embalagem
BR112014024437A2 (pt) método para produzir bis (ss-epoxipropil) - sulfeto e bis (ss-epoxipropil) polissulfeto.
BR112014031785A2 (pt) composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112015010295A2 (pt) método para operar um compressor e produto de programa de computador.